Tirzepatide 50mg Research Peptide
Tirzepatide is a dual GIP/GLP-1 receptor agonist (twincretin) developed by Eli Lilly and approved by the FDA in 2022 for type 2 diabetes (Mounjaro) and in 2023 for obesity (Zepbound). It is a synthetic 39-amino acid peptide that acts as an agonist at both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R), producing synergistic metabolic effects that exceed those of selective GLP-1 agonists in clinical trials. This 50mg vial provides research-grade tirzepatide at ≥99% purity, HPLC and MS/MS verified per batch, for in vitro and preclinical research applications.
Research Background
The SURPASS clinical trial program established tirzepatide’s efficacy profile across type 2 diabetes populations, demonstrating superior HbA1c reduction and weight loss versus comparator GLP-1 agonists including semaglutide. The SURMOUNT program in obesity demonstrated up to 22.5% mean weight reduction at 72 weeks in the highest dose cohort — outcomes that exceeded all previously approved anti-obesity agents at the time of approval. As the first FDA-approved dual incretin receptor agonist, tirzepatide serves as a key reference compound for GIP/GLP-1 synergy research and a benchmark for emerging triple agonist compounds including retatrutide.
Compound Specifications
- Format: Lyophilized powder
- Purity: ≥99% (HPLC verified)
- Quantity: 50mg per vial
- Storage: −20°C, protected from light
- CAS Number: 2023788-19-2
- Molecular Weight: 4813.5 Da
Certificate of Analysis
All tirzepatide vials are third-party tested by independent ISO-certified laboratories. HPLC and MS/MS validation performed per batch. COA available on request.
For research and laboratory use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
